相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy
Ashley E. Mahne et al.
CANCER RESEARCH (2017)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2017)
The future of immune checkpoint cancer therapy after PD-1 and CTLA-4
Andrew W. Hahn et al.
IMMUNOTHERAPY (2017)
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization
Di Zhang et al.
MABS (2017)
Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling
Cristian R. Smulski et al.
CELL DEATH & DISEASE (2017)
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
Dmitriy Zamarin et al.
NATURE COMMUNICATIONS (2017)
Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis
Rajeev K. Shrimali et al.
CANCER IMMUNOLOGY RESEARCH (2017)
MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential
Natalie J. Tigue et al.
ONCOIMMUNOLOGY (2017)
GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory
Nick M. Durham et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
David J. Messenheimer et al.
CLINICAL CANCER RESEARCH (2017)
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells
Selvakumar Sukumar et al.
CANCER RESEARCH (2017)
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
Rebecca Leyland et al.
CLINICAL CANCER RESEARCH (2017)
Influence of immunoglobulin isotype on therapeutic antibody function
Stephen A. Beers et al.
BLOOD (2016)
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Haidong Tang et al.
CANCER CELL (2016)
Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy
Kieu-Suong Le et al.
CANCER RESEARCH (2016)
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection
Todd C. Metzger et al.
CANCER RESEARCH (2016)
Rationale for anti-GITR cancer immunotherapy
Deborah A. Knee et al.
EUROPEAN JOURNAL OF CANCER (2016)
Rationale for anti-OX40 cancer immunotherapy
Sandrine Aspeslagh et al.
EUROPEAN JOURNAL OF CANCER (2016)
CD28 Costimulation: From Mechanism to Therapy
Jonathan H. Esensten et al.
IMMUNITY (2016)
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
Qianxia Zhang et al.
IMMUNITY (2016)
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
George Plitas et al.
IMMUNITY (2016)
Despite slow progress, bispecifics generate buzz
Cormac Sheridan
NATURE BIOTECHNOLOGY (2016)
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
NATURE REVIEWS DRUG DISCOVERY (2016)
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer
Ryan Montler et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2016)
Engineered T cells: the promise and challenges of cancer immunotherapy
Andrew D. Fesnak et al.
NATURE REVIEWS CANCER (2016)
Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies
Ann L. White et al.
CANCER CELL (2015)
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
David J. DiLillo et al.
CELL (2015)
Principles of antibody-mediated TNF receptor activation
H. Wajant
CELL DEATH AND DIFFERENTIATION (2015)
Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors
Cariad Chester et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
FcγR requirements leading to successful immunotherapy
Lekh N. Dahal et al.
IMMUNOLOGICAL REVIEWS (2015)
Bispecific antibodies and their applications
Gaowei Fan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Integrated molecular analysis of adult T cell leukemia/lymphoma
Keisuke Kataoka et al.
NATURE GENETICS (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model
Sachin Gupta et al.
VACCINE (2015)
4-1 BB agonists: multi-potent potentiators of tumor immunity
Todd Bartkowiak et al.
FRONTIERS IN ONCOLOGY (2015)
OX40 agonists anc combination immunotherapy: putting the pedal to the metal
Stefanie N. Linch et al.
FRONTIERS IN ONCOLOGY (2015)
Upregulation of Fc gamma RIIb on monocytes is necessary to promote the superagonist activity of TGN1412
Khiyam Hussain et al.
BLOOD (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Regulation of tumour necrosis factor signalling: live or let die
Dirk Brenner et al.
NATURE REVIEWS IMMUNOLOGY (2015)
The Immunological Synapse: A Molecular Machine Controlling T Cell Activation
Arash Grakoui et al.
JOURNAL OF IMMUNOLOGY (2015)
Colloidal Drug Formulations Can Explain Bell-Shaped Concentration-Response Curves
Shawn C. Owen et al.
ACS CHEMICAL BIOLOGY (2014)
Regulatory T cells in cancer immunotherapy
Hiroyoshi Nishikawa et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future
Lisa M. Sedger et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08
Paula Tabares et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Yannick Bulliard et al.
IMMUNOLOGY AND CELL BIOLOGY (2014)
CD80 and CD86 IgC domains are important for quaternary structure, receptor binding and co-signaling function
Tanya Girard et al.
IMMUNOLOGY LETTERS (2014)
Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer
Vanessa Gauttier et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
被撤回的出版物: Targeting CD137 enhances the efficacy of cetuximab (Retracted article. See vol. 129, pg. 2595, 2019)
Holbrook E. Kohrt et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Xiaozhou Fan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization
Ann L. White et al.
JOURNAL OF IMMUNOLOGY (2014)
Cell Contact-Dependent Priming and Fc Interaction with CD32+ Immune Cells Contribute to the TGN1412-Triggered Cytokine Response
Patrick Bartholomaeus et al.
JOURNAL OF IMMUNOLOGY (2014)
Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death
Kim L. Brunekreeft et al.
MOLECULAR CANCER (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
Lee P. Richman et al.
CANCER IMMUNOLOGY RESEARCH (2014)
IgG subclasses and allotypes: from structure to effector functions
Gestur Vidarsson et al.
FRONTIERS IN IMMUNOLOGY (2014)
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
Ignacio Melero et al.
CLINICAL CANCER RESEARCH (2013)
Agonistic CD40 Antibodies and Cancer Therapy
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2013)
Fc gamma receptors enable anticancer action of proapoptotic and immune-modulatory antibodies
Jeong M. Kim et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27-Transgenic Mice
Li-Zhen He et al.
JOURNAL OF IMMUNOLOGY (2013)
Engineered antibody Fc variant with selectively enhanced FcRIIb binding over both FcRIIaR131 and FcRIIaH131
F. Mimoto et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2013)
Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation
Henning Walczak
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H. Vonderheide et al.
ONCOIMMUNOLOGY (2013)
Pharmacological modulation of GITRL/GITR system: therapeutic perspectives
Giuseppe Nocentini et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
Timothy S. Fisher et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells
Julien Faget et al.
CANCER RESEARCH (2012)
CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth
Christina Claus et al.
CANCER RESEARCH (2012)
A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency
M. Chodorge et al.
CELL DEATH AND DIFFERENTIATION (2012)
Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia
Laura A. Vitale et al.
CLINICAL CANCER RESEARCH (2012)
被撤回的出版物: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer (Retracted article. See vol. 129, pg. 2595, 2019)
Holbrook E. Kohrt et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Impact of Epidermal Growth Factor Receptor (EGFR) Cell Surface Expression Levels on Effector Mechanisms of EGFR Antibodies
Stefanie Derer et al.
JOURNAL OF IMMUNOLOGY (2012)
Association of OX40L Polymorphisms with Sporadic Breast Cancer in Northeast Chinese Han Population
Yuan Weiguang et al.
PLOS ONE (2012)
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement
Fubin Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Association between genetic variations in tumor necrosis factor receptor genes and survival of patients with T-cell lymphoma
Kan Zhai et al.
CHINESE JOURNAL OF CANCER (2012)
Response to 'Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial'
Thomas Huenig
NATURE REVIEWS IMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
被撤回的出版物: CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies (Retracted article. See vol. 134, pg. 658, 2019)
Holbrook E. Kohrt et al.
BLOOD (2011)
Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412
Paula S. Roemer et al.
BLOOD (2011)
An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
Nicholas S. Wilson et al.
CANCER CELL (2011)
B7-H2 Is a Costimulatory Ligand for CD28 in Human
Sheng Yao et al.
IMMUNITY (2011)
Science gone translational: the OX40 agonist story
Andrew D. Weinberg et al.
IMMUNOLOGICAL REVIEWS (2011)
Stimulation of the Glucocorticoid-Induced TNF Receptor Family-Related Receptor on CD8 T Cells Induces Protective and High-Avidity T Cell Responses to Tumor-Specific Antigens
Anik L. Cote et al.
JOURNAL OF IMMUNOLOGY (2011)
Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
Ann L. White et al.
JOURNAL OF IMMUNOLOGY (2011)
Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function
Jessica Ann Hernandez-Chacon et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Protective Effector Memory CD4 T Cells Depend on ICOS for Survival
Tamson V. Moore et al.
PLOS ONE (2011)
Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
Michael A. Curran et al.
PLOS ONE (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
Fubin Li et al.
SCIENCE (2011)
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L. Nordstrom et al.
BREAST CANCER RESEARCH (2011)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells
D. Eastwood et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors
Jens Rueter et al.
CANCER BIOLOGY & THERAPY (2010)
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ
Juan Dubrot et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
Bradley C. Carthon et al.
CLINICAL CANCER RESEARCH (2010)
The Structure of the Trimer of Human 4-1BB Ligand Is Unique among Members of the Tumor Necrosis Factor Superfamily
Eun-Young Won et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
CD137-Mediated Pathogenesis from Chronic Hepatitis to Hepatocellular Carcinoma in Hepatitis B Virus-Transgenic Mice
Jun Wang et al.
JOURNAL OF IMMUNOLOGY (2010)
CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893
Anusha Kalbasi et al.
JOURNAL OF IMMUNOTHERAPY (2010)
An Enigmatic Tail of CD28 Signaling
Jonathan S. Boomer et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Anti-CD30 Antibodies for Hodgkin Lymphoma
Kelley V. Foyil et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
LIGHT protein suppresses tumor growth by augmentation of immune response
Tomohiro Morishige et al.
IMMUNOLOGY LETTERS (2009)
Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand
Agnes Wyzgol et al.
JOURNAL OF IMMUNOLOGY (2009)
Impaired CD4 and CD8 Effector Function and Decreased Memory T Cell Populations in ICOS-Deficient Patients
Naomi Takahashi et al.
JOURNAL OF IMMUNOLOGY (2009)
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues
Hong Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer
Claudia M. Dollins et al.
CHEMISTRY & BIOLOGY (2008)
Toward experimental assessment of receptor occupancy: TGN1412 revisited
Zoe Waibler et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
Multivalent 4-1BB binding aptamers costimulate CD8(+) T cells and inhibit tumor growth in mice
James O. McNamara et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Silvia Piconese et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
ICOS ligation recruits the p50α PI3K regulatory subunit to the immunological synapse
Camille Fos et al.
JOURNAL OF IMMUNOLOGY (2008)
Structural basis for ligand-mediated mouse GITR activation
Zhaocai Zhou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states
Zhaocai Zhou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response
Isabelle Miconnet et al.
VACCINE (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Pivotal roles of CD4+ effector T cells in mediating agonistic Anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors
Pengfei Zhou et al.
JOURNAL OF IMMUNOLOGY (2007)
Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb
Betty Li et al.
CLINICAL IMMUNOLOGY (2007)
Cytokine Storm in the phase I trial of monoclonal antibody TGN1412: Better understanding the causes to improve preclinical testing of immunotherapeutics
Richard Stebbings et al.
JOURNAL OF IMMUNOLOGY (2007)
Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain
Nicholas P. Morris et al.
MOLECULAR IMMUNOLOGY (2007)
Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice
Liguo Niu et al.
JOURNAL OF IMMUNOLOGY (2007)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H. Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Antibodies, Fc receptors and cancer
Falk Nimmerjahn et al.
CURRENT OPINION IN IMMUNOLOGY (2007)
Activating and inhibitory FcγRs in autoimmune disorders
Falk Nimmerjahn
SPRINGER SEMINARS IN IMMUNOPATHOLOGY (2006)
Structural basis of inducible costimulator ligand costimulatory function: Determination of the cell surface oligomeric state and functional mapping of the receptor binding site of the protein
Kausik Chattopadhyay et al.
JOURNAL OF IMMUNOLOGY (2006)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists
Bing Li et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
The kinetic-segregation model: TCR triggering and beyond
Simon J. Davis et al.
NATURE IMMUNOLOGY (2006)
The crystal structure of the costimulatory OX40-OX40L complex
Deanne M. Compaan et al.
STRUCTURE (2006)
CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism
John J. Engelhardt et al.
JOURNAL OF IMMUNOLOGY (2006)
B7-1 and B7-2: Similar costimulatory ligands with different biochemical, oligomeric and signaling properties
S Bhatia et al.
IMMUNOLOGY LETTERS (2006)
Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines
GW Stone et al.
JOURNAL OF VIROLOGY (2006)
The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games
T Hehlgans et al.
IMMUNOLOGY (2005)
Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity:: a novel regulatory role for OX40 and its comparison with GITR
B Valzasina et al.
BLOOD (2005)
A distinct role for ICOS-mediated co-stimulatory signaling in CD4+ and CD8+ T cell subsets
M Watanabe et al.
INTERNATIONAL IMMUNOLOGY (2005)
Crystal structure of a soluble CD28-Fab complex
EJ Evans et al.
NATURE IMMUNOLOGY (2005)
Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells
I Takeda et al.
JOURNAL OF IMMUNOLOGY (2004)
Priming of naive T cells inside tumors leads to eradication of established tumors
P Yu et al.
NATURE IMMUNOLOGY (2004)
The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of integrin LFA-1
CF Lu et al.
JOURNAL OF IMMUNOLOGY (2004)
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse
T Pentcheva-Hoang et al.
IMMUNITY (2004)
The role of the CD40 pathway in the pathogenesis and treatment of cancer
AG Eliopoulos et al.
CURRENT OPINION IN PHARMACOLOGY (2004)
ICOS deficiency in patients with common variable immunodeficiency
U Salzer et al.
CLINICAL IMMUNOLOGY (2004)
TRAIL and its receptors as targets for cancer therapy
H Yagita et al.
CANCER SCIENCE (2004)
Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists
F Lühder et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Crystal structure of the receptor-binding domain of human B7-2: Insights into organization and signaling
XW Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Potent activity of soluble B7RP-1-FC in therapy of murine tumors in syngeneic hosts
G Ara et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex
N Holler et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
OH Brekke et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
A Ashkenazi
NATURE REVIEWS CANCER (2002)
Structural mechanisms of costimulation
JCD Schwartz et al.
NATURE IMMUNOLOGY (2002)
T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody
AL Tutt et al.
JOURNAL OF IMMUNOLOGY (2002)
Stimulation of CD25+CD4+regulatory T cells through GITR breaks immunological self-tolerance
J Shimizu et al.
NATURE IMMUNOLOGY (2002)
The molecular architecture of the TNF superfamily
JL Bodmer et al.
TRENDS IN BIOCHEMICAL SCIENCES (2002)
The TNF-receptor-associated factor family - Scaffold molecules for cytokine receptors, kinases and their regulators
H Wajant et al.
CELLULAR SIGNALLING (2001)
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex
JCD Schwartz et al.
NATURE (2001)
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
CC Stamper et al.
NATURE (2001)
The TNF and TNF receptor superfamilies: Integrating mammalian biology
RM Locksley et al.
CELL (2001)
CD40 ligation for immunotherapy of solid tumours
SM Todryk et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
ICOS is essential for effective T-helper-cell responses
A Tafuri et al.
NATURE (2001)
The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity
RM Siegel et al.
NATURE IMMUNOLOGY (2000)
CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily
AG Eliopoulos et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling
FKM Chan et al.
SCIENCE (2000)
LICOS, a primordial costimulatory ligand?
D Brodie et al.
CURRENT BIOLOGY (2000)
Gene structure and chromosomal assignment of mouse GITR, a member of the tumor necrosis factor/nerve growth factor receptor family
G Nocentini et al.
DNA AND CELL BIOLOGY (2000)
Cutting edge: Identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor
V Ling et al.
JOURNAL OF IMMUNOLOGY (2000)
Structure and dimerization of a soluble form of B7-1
S Ikemizu et al.
IMMUNITY (2000)
分享论文
